BHC · Bausch Health Companies Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on BHC. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About BHC · Bausch Health Companies Inc.
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Live Quote
SELL (score -6) · 12-1 mom -12.1% · RSI 36.9 · below_both · -42.4% from high
Targets blend Wall Street consensus (5 analysts: low $6.00 / mean $7.40 / high $9.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
BHC triggered on an insider cluster signal that ultimately resolved to director RSU grants (not open-market purchases) plus one director selling shares at market. The company operates a diversified specialty pharma business with strong franchises in gastroenterology (Xifaxan), dermatology, and ophthalmology via Bausch+Lomb. Valuation is cheap on a forward P/E of 1.33x and EV/EBITDA of 6.2x relative to the specialty-generic sector — but this low multiple reflects $20.8B in net debt against ~$3.5-4B EBITDA (net debt/EBITDA ~14x), an ongoing Xifaxan antitrust lawsuit, and a stock down -20% YTD from the 52-week high of $8.69. Q1 2026 revenue grew 14% but EPS missed consensus by -3%, and next earnings are July 29, 2026 — nearly 9 weeks away with no named near-term catalyst to force re-rating.